While ERβ is expressed in epithelial, myoepithelial and stromal cells of breast tissue during development and in adulthood, its levels have been reported to decline in breast cancer [10–14] due to oncogenic signaling that primarily represses the activity of the promoter of the ERβ gene [14,15]. The gene discussed is ESR2; the disease is breast carcinoma.